GGrantIndex
← Search

EARLY-PHASE STUDY TO EVALUATE MEK AND MDM2 INHIBITION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 AND PREMALIGNANT AND MALIGNANT PERIPHERAL NERVE SHEATH TUMORS

$1,393,487FY2022Department of the ArmyDOD

Children'S Research Institute, Washington DC

Investigators

View source on USAspending →
EARLY-PHASE STUDY TO EVALUATE MEK AND MDM2 INHIBITION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 AND PREMALIGNANT AND MALIGNANT PERIPHERAL NERVE SHEATH TUMORS · GrantIndex